NCT03959436View on ClinicalTrials.gov

Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery

CompletedOBSERVATIONAL

Enrollment

612

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions

CarbetocinCesarean Section ComplicationsUterotonicsUterine Atony With Hemorrhage

Interventions

DRUG

Carbetocin

Carbetocin as the primary uterotonic for all cesarean sections

Trial Locations (1)

H1T 2M4

Maisonneuve-Rosemont hospital, Montreal

Sponsors

Collaborators (1)

Ferring Pharmaceuticals

All Listed Sponsors

collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Maisonneuve-Rosemont Hospital

OTHER